Last reviewed · How we verify
NCT04282278
Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor
Phase 2 trial testing Camrelizumab/sintilimab+ Standard chemotherapy in Advanced Solid Tumor in 180 participants. Status unknown.
1 April 2022
Quick facts
| Lead sponsor | Hebei Medical University Fourth Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 16 July 2020 |
| Primary completion | 1 April 2022 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab/sintilimab+ Standard chemotherapy — full drug profile →
- Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy） — full drug profile →
- Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Hebei Medical University Fourth Hospital
Who can join
Adults 18 to 70, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess time window, efficacy and safety of patients who receive anti-PD-1 antibody multimodal combination as first-line treatment of advanced solid tumor.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma.
Just MA, Van Mater D, Wagner LM. · · 2021 · cited 23× · PMID 33894051 · DOI 10.1002/pbc.29084
Verify or expand the search:
- PubMed search for NCT04282278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Hebei Medical University Fourth Hospital trials
Trials by the same sponsor.
- NCT05522491 — Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Br · Phase 2 · not yet recruiting
- NCT07448077 — Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC · Phase 2 · not yet recruiting
- NCT07410611 — ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy · Phase 2 · not yet recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
- NCT07492394 — Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04282278 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Medical University Fourth Hospital
- Last refreshed: 10 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04282278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing